Dr. Aiping Zhou 周爱萍
Chief Physician
Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences (National Cancer Center), Beijing
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Chemotherapy and biological targeted therapy for malignant tumors, including lung cancer, breast cancer, and gastrointestinal tumors. Specializes in medical treatment for gastrointestinal tumors and renal cell carcinoma.
Dr. Zhou holds a medical doctorate and serves as a Chief Physician. Expertise includes chemotherapy and biological targeted therapy for various malignant tumors, with in-depth research in the medical treatment of gastrointestinal tumors and renal cell carcinoma.
Name order: in Chinese the family name comes first (Zhou Aiping). Papers usually list the name as Aiping Zhou or Zhou A.
Selected publications
121 papers on PubMed matched by name and affiliation; 28 as first or senior author since 2016. Most recent first- or senior-author papers:
- Clin Pharmacol Drug Dev, 2026 (senior author): A Phase I Study of Nimotuzumab Combined with Irinotecan in Chinese Patients with Advanced Solid Tumors. PubMed 42811448
- Front Oncol, 2026 (senior author): Case Report: Patient-derived organoids guiding dabrafenib-trametinib therapy in BRAF(V600E)-mutant metastatic gastric cancer. PubMed 42245692
- Ther Adv Med Oncol, 2025 (senior author): Serum BDNF helps identify favorable subgroups in HCC patients treated with PD-L1 inhibitors and anti-angiogenic TKIs. PubMed 41466842
- Hum Vaccin Immunother, 2025 (senior author): Cost-effectiveness of trastuzumab deruxtecan as a second-line treatment for HER2-mutant advanced non-small cell lung cancer. PubMed 39989197
- Cancer Immunol Immunother, 2025 (senior author): Fruquintinib plus sintilimab in previously bevacizumab-treated, pMMR/MSS refractory metastatic colorectal cancer: a phase 2 clinical trial. PubMed 41264024
- Curr Oncol, 2025 (senior author): Tumor Immune Microenvironment and Current Status of Immune Checkpoint Inhibitor Therapy in Colorectal Cancer Liver Metastasis. PubMed 41002563
- Lancet Oncol, 2025 (first author): First-line benmelstobart plus anlotinib versus sunitinib in advanced renal cell carcinoma (ETER100): a multicentre, randomised, open-label, phase 3 trial. PubMed 40907513
- J Gastrointest Oncol, 2024 (senior author): Regorafenib monotherapy as the later-line treatment for elderly patients with metastatic colorectal cancer: a multicenter real-world study. PubMed 39554563
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion